Background: Foreign body granuloma (FBG) formation is linked to chronic persistent cutaneous inflammation, representing a severe delayed complication characterized histologically by infiltration of multinucleated giant cells and aggregation of lymphocytes. In filler-induced FBG following cosmetic injections, implanted materials represent a key driver of sustained inflammatory responses. Achieving complete resolution remains challenging, with current therapeutic outcomes for FBG being suboptimal. Emerging evidence suggests that Janus kinase (JAK) inhibitors may constitute a promising therapeutic strategy for refractory granulomatous conditions. Objective: This case report describes the successful management of FBG using JAK inhibitors and synthesizes existing literature to evaluate the efficacy, safety, and potential mechanisms of abrocitinib in treating filler-induced cutaneous FBG. Methods: We present a case of post-filler FBG that presents with multiple smooth-surfaced, hemispherical lesions (3– 5 mm in diameter) distributed across the entire facial region. The patient was treated with oral abrocitinib (100 mg daily) and prednisone (30 mg daily, tapered over 9 weeks). Clinical outcomes were assessed weekly for 13 weeks through serial clinical photography, dermoscopy, reflectance confocal microscopy, and multispectral imaging. Adverse events, including rash exacerbation, vomiting, dizziness, and fever, were systematically monitored. A comprehensive literature review was conducted to elucidate JAK inhibitors’ therapeutic rationale in filler-associated FBG. Results: The patient achieved complete granuloma resolution within 13 weeks following failed corticosteroid monotherapy. No treatment-related adverse effects were observed during the one-month follow-up period, supporting the favorable safety profile of this therapeutic approach. Conclusion: This report provides preliminary evidence for JAK inhibitors’ efficacy in managing refractory filler-induced FBG. Large-scale controlled trials are warranted to validate long-term safety and therapeutic benefits.
1 January 2023 in Clinical, Cosmetic and Investigational Dermatology
Minocycline is a tetracycline derivative antibiotic commonly used to treat acne, rosacea, and other inflammatory skin conditions. Taking minocycline risks inducing skin pigmentation. If minocycline-induced hyperpigmentation is not treated, it may take months to years for the symptoms to subside after discontinuation of the drug, or the hyperpigmentation may never disappear completely, which can lead to cosmetic anxiety and affect people’s quality of life. Previous treatment options for hyperpigmentation were mainly q-switched nd: YAG, ruby, and alexandrite lasers. This article reports a case of facial hyperpigmentation caused by minocycline using a combination of chemical peel and intense pulsed light in a patient with eosinophilic cellulitis (Wells syndrome) who was taking oral minocycline. This case suggests combining chemical peel and intense pulsed light is an effective treatment option for minocycline-induced hyperpigmentation.
1 August 2021 in Clinical, Cosmetic and Investigational Dermatology
Reports of immune-related adverse events caused by programmed cell death protein-1 inhibitor are becoming increasingly frequent. Herein, we report the first case of pemphigus herpetiformis-type drug reaction presented after the treatment of tislelizumab (6 cycles) in a primary non-small cell lung carcinoma patient. A 56-year-old Chinese man was referred to our department for pruritic annulare erythema and blister for two weeks. Histological finding revealed blister formation in the epidermis and eosinophilic infiltration in the blister fluid. Direct immunofluorescence showed intercellular deposition of IgG and C3 within the lower part of epidermis. Serum anti-intercellular antibodies were positive at 1:100 dilution. Based on history and clinicopathological correlation, herpetiformis-type drug-induced pemphigus was diagnosed, which was possibly be induced by tislelizumab. To the best to our knowledge, there is no report of pemphigus herpetiformis-type drug-induced reaction associated with programmed cell death protein-1 inhibitor treatment.
15 December 2023 in Journal of the European Academy of Dermatology and Venereology
We conducted a retrospective analysis of clinical and pathologic data from January 2020 to June 2023, focusing on 10 patients diagnosed with eosinophilic pustular folliculitis at our dermatology clinic. Four of the ten patients had the first rash on the face, five on the trunk, and one on the palms and feet, all of which were initially scattered papules that gradually increased and fused into erythematous plaques with a circular distribution. Seven had pustules with small surface desquamation, and three cases had micro swelling on the face. The rash involved only the face in 5 cases, the face and trunk in 5 cases, and the face, trunk, hands, and feet in 1 case. Seven of the ten patients were pruritic, and 3 had no obvious pruritus. The histopathological features were mild epidermal hyperplasia, lymphocytic and eosinophilic infiltration around the superficial middle dermal vessels and appendages, and eosinophilic and neutrophilic abscesses in the local hair follicles. Treatment with oral indomethacin, prednisone, and minocycline was effective.